IN2014DN08562A - - Google Patents

Info

Publication number
IN2014DN08562A
IN2014DN08562A IN8562DEN2014A IN2014DN08562A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A IN 8562DEN2014 A IN8562DEN2014 A IN 8562DEN2014A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A
Authority
IN
India
Prior art keywords
sert
prodrugs
pharmaceutically acceptable
acceptable salt
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Sharon Mates
Robert Davis
Peng Li
Lawrence Wennogle
Richard A Lerner
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IN2014DN08562A publication Critical patent/IN2014DN08562A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IN8562DEN2014 2012-04-14 2013-04-14 IN2014DN08562A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261624292P 2012-04-14 2012-04-14
US201261624293P 2012-04-14 2012-04-14
US201261624291P 2012-04-14 2012-04-14
US201261671723P 2012-07-14 2012-07-14
US201261671713P 2012-07-14 2012-07-14
PCT/US2013/036514 WO2013155505A1 (fr) 2012-04-14 2013-04-14 Composés organiques

Publications (1)

Publication Number Publication Date
IN2014DN08562A true IN2014DN08562A (fr) 2015-05-22

Family

ID=49328233

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8562DEN2014 IN2014DN08562A (fr) 2012-04-14 2013-04-14

Country Status (13)

Country Link
US (8) US9428506B2 (fr)
EP (4) EP3791879A1 (fr)
JP (6) JP6242855B2 (fr)
KR (1) KR20140146192A (fr)
CN (1) CN104519886B (fr)
AU (1) AU2013245702A1 (fr)
CA (1) CA2870303A1 (fr)
ES (1) ES2727815T3 (fr)
HK (1) HK1206630A1 (fr)
IN (1) IN2014DN08562A (fr)
MX (1) MX2014012374A (fr)
RU (1) RU2014145682A (fr)
WO (3) WO2013155506A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112280A1 (fr) 2007-03-12 2008-09-18 Intra-Cellular Therapies, Inc. Synthèse de gamma-carbolines fusionnées à hétérocycles substitués
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
US8598119B2 (en) 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
JP5894574B2 (ja) 2010-04-22 2016-03-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2013119800A1 (fr) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Utilisation d'antagonistes de ghréline ou de récepteur de ghréline pour prévenir ou traiter une maladie psychiatrique sensible au stress
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014145192A1 (fr) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Composés organiques
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN111689966A (zh) 2014-04-04 2020-09-22 细胞内治疗公司 有机化合物
KR20170012209A (ko) * 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN104003987B (zh) * 2014-06-03 2016-03-23 中国药科大学 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US20170007618A1 (en) * 2015-06-17 2017-01-12 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
IL296884B2 (en) 2016-01-26 2024-05-01 Intra Cellular Therapies Inc Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
HUE055334T2 (hu) * 2016-03-25 2021-11-29 Intra Cellular Therapies Inc Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében
WO2017172784A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouveaux sels et cristaux
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US11433253B2 (en) 2017-02-15 2022-09-06 The Regents Of The University Of California Light therapy system and methods of use
JP7458786B2 (ja) * 2017-02-15 2024-04-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善された光療法システムおよび使用方法
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
CN110636845A (zh) * 2017-04-10 2019-12-31 雷迪博士实验室有限公司 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体
CA3071119A1 (fr) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Gamma-carbolines fusionnees a heterocycles substituees pour le traitement ou la prophylaxie de troubles du systeme nerveux central
MX2020000967A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
MX2020007271A (es) 2017-09-26 2020-08-17 Intra Cellular Therapies Inc Sales y cristales novedosos.
CA3094204A1 (fr) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Nouveaux procedes
AU2019262579A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Salts of an FGFR inhibitor
CA3102948A1 (fr) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Nouvelles methodes
WO2019241278A1 (fr) * 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Synthèse de gamma-carbolines fusionnées à hétérocycles substitués
WO2019246384A1 (fr) 2018-06-21 2019-12-26 Aquestive Therapeutics, Inc. Système et procédé de fabrication de doses unitaires individuelles personnalisées contenant des agents actifs pharmaceutiques
AU2019328528A1 (en) * 2018-08-31 2021-03-18 Intra-Cellular Therapies, Inc. Novel methods
KR20210052472A (ko) * 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
WO2020051317A1 (fr) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Compositions de film oral et formes posologiques ayant des profils de dissolution actifs précis
US20210000822A1 (en) 2019-07-07 2021-01-07 Intra-Cellular Therapies, Inc. Novel methods
JP2022554293A (ja) 2019-11-01 2022-12-28 アクエスティブ セラピューティクス インコーポレイテッド プロドラッグ組成物及び治療方法
EP4058029A1 (fr) 2019-11-14 2022-09-21 Aquestive Therapeutics, Inc. Compositions multimodales et méthodes de traitement
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN116940351A (zh) 2021-01-15 2023-10-24 阿奎斯蒂弗医疗股份有限公司 前药组合物和治疗方法
WO2022192476A1 (fr) 2021-03-09 2022-09-15 Aquestive Therapeutics, Inc. Formes pharmaceutiques ayant des profils biocomparables équivalents
WO2023225620A1 (fr) 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Nouveaux procédés

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3606908A (en) 1969-11-26 1971-09-21 Trico Products Corp Ventilation system for volatile fluid
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
JPS5014494A (fr) * 1973-06-11 1975-02-15
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
SE8304361D0 (sv) * 1983-08-10 1983-08-10 Ferrosan Ab Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS6175A (ja) * 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
ZA871987B (en) 1986-03-19 1988-05-25 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same
JP2641443B2 (ja) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ES2236700T3 (es) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
WO1999018057A1 (fr) 1997-10-06 1999-04-15 Massachusetts Institute Of Technology Preparation de diaryl ethers par reactions de condensation
JP4647780B2 (ja) 1998-02-26 2011-03-09 マサチューセッツ インスティテュート オブ テクノロジー ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
WO2000002887A2 (fr) 1998-07-10 2000-01-20 Massachusetts Institute Of Technology Ligands pour metaux et processus perfectionnes catalyses par des metaux bases sur ceux-ci
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
MXPA01006108A (es) 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
JP4762465B2 (ja) * 1999-06-15 2011-08-31 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
HUP0303432A3 (en) 2000-12-20 2012-09-28 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
DK2275395T3 (en) 2001-04-24 2017-02-20 Massachusetts Inst Of Tech (Mit) Copper-catalyzed provision of carbon-carbon compounds.
BR0211608A (pt) 2001-08-08 2006-04-04 Upjohn Co 1h-pirido[4,3-b]indóis terapêuticos
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004010981A1 (fr) 2002-07-29 2004-02-05 Alza Corporation Techniques et formes de dose d'apport commande de paliperidone
US6888032B2 (en) 2002-08-02 2005-05-03 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
EP1581221B1 (fr) 2002-12-19 2011-05-18 Bristol-Myers Squibb Company Gamma-carbolines tricycliques substituees utilisees comme agonistes et antagonistes du recepteur de la serotonine
CN101780080B (zh) 2003-01-16 2014-06-04 阿卡蒂亚药品公司 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
ATE411980T1 (de) 2003-07-21 2008-11-15 Smithkline Beecham Corp (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US20080280941A1 (en) 2004-03-05 2008-11-13 Pierre Lourtie 8-Phenoxy-Gamma Carboline Derivatives
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
EP1793671B1 (fr) * 2004-09-20 2011-04-27 Mount Sinai School of Medicine Utilisation de memantine (namenda) pour traiter l'autisme, les etats compulsifs et impulsifs
JP2008513432A (ja) * 2004-09-21 2008-05-01 ファイザー・プロダクツ・インク Ｃｎｓ状態の治療に有用なｎ−メチルヒドロキシエチルアミン
ATE457989T1 (de) 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
CN103467471A (zh) * 2005-06-06 2013-12-25 武田药品工业株式会社 有机化合物
WO2008112280A1 (fr) 2007-03-12 2008-09-18 Intra-Cellular Therapies, Inc. Synthèse de gamma-carbolines fusionnées à hétérocycles substitués
CN101842010A (zh) 2007-08-01 2010-09-22 梅迪维新神经学公司 使用抗精神病的组合治疗产品来治疗精神***症的方法和组合物
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
PL2262505T3 (pl) * 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
US8598119B2 (en) * 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
JP5894574B2 (ja) 2010-04-22 2016-03-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9428506B2 (en) * 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US10011602B2 (en) 2012-07-06 2018-07-03 The University Of Melbourne Immunological reagents and uses therefor
WO2014145192A1 (fr) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Composés organiques
US9161061B2 (en) 2013-03-15 2015-10-13 Pictech Management Limited Data storage and exchange device for color space encoded images
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20170012209A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN111689966A (zh) 2014-04-04 2020-09-22 细胞内治疗公司 有机化合物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
IL296884B2 (en) 2016-01-26 2024-05-01 Intra Cellular Therapies Inc Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
HUE055334T2 (hu) 2016-03-25 2021-11-29 Intra Cellular Therapies Inc Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében
WO2017172784A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouveaux sels et cristaux
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
CA3071119A1 (fr) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Gamma-carbolines fusionnees a heterocycles substituees pour le traitement ou la prophylaxie de troubles du systeme nerveux central
MX2020000967A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.

Also Published As

Publication number Publication date
EP3791879A1 (fr) 2021-03-17
JP2023159345A (ja) 2023-10-31
JP6242855B2 (ja) 2017-12-06
EP2836213A1 (fr) 2015-02-18
JP2015514135A (ja) 2015-05-18
JP2015516395A (ja) 2015-06-11
EP2836212A1 (fr) 2015-02-18
US20150079172A1 (en) 2015-03-19
US20150072964A1 (en) 2015-03-12
US9428506B2 (en) 2016-08-30
WO2013155505A1 (fr) 2013-10-17
JP2021098724A (ja) 2021-07-01
ES2727815T3 (es) 2019-10-18
US20200407362A1 (en) 2020-12-31
EP2836211A4 (fr) 2015-09-09
WO2013155504A1 (fr) 2013-10-17
EP2836212A4 (fr) 2015-09-09
WO2013155506A1 (fr) 2013-10-17
EP2836211B1 (fr) 2019-03-20
US11958852B2 (en) 2024-04-16
MX2014012374A (es) 2015-04-17
US20240208974A1 (en) 2024-06-27
CN104519886A (zh) 2015-04-15
AU2013245702A1 (en) 2014-11-13
JP6334511B2 (ja) 2018-05-30
US20210371421A1 (en) 2021-12-02
JP2018168161A (ja) 2018-11-01
EP2836213A4 (fr) 2015-09-09
JP2015512951A (ja) 2015-04-30
US11053245B2 (en) 2021-07-06
US20150080404A1 (en) 2015-03-19
US20210002280A1 (en) 2021-01-07
KR20140146192A (ko) 2014-12-24
EP2836211A1 (fr) 2015-02-18
US20200017499A1 (en) 2020-01-16
US11124514B2 (en) 2021-09-21
HK1206630A1 (en) 2016-01-15
RU2014145682A (ru) 2016-06-10
EP2836213B1 (fr) 2018-07-04
CN104519886B (zh) 2017-09-12
CA2870303A1 (fr) 2013-10-17

Similar Documents

Publication Publication Date Title
IN2014DN08562A (fr)
MX2021010306A (es) Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso.
MX2021013564A (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2012012277A (es) Compuestos organicos.
MX2016013046A (es) Compuestos organicos.
MX2020000968A (es) Compuestos organicos.
MX2020000967A (es) Compuestos organicos.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX348823B (es) Formulaciones estables de linaclotida.
PH12015500823A1 (en) Modified release formulations for oprozomib
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2020009929A (es) Compuestos organicos.
UA118562C2 (uk) Модулятори рецептора cxcr7
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
PH12017501736A1 (en) Indole derivatives
MX2021007217A (es) Compuesto organico.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
PH12016502540A1 (en) Pharmaceutical dosage forms
GR1008169B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine
MX2015013279A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
IN2013MU03838A (fr)
IN2013MU01239A (fr)